Using Bayesian-PBPK modeling for assessment of inter-individual variability and subgroup stratification

PURPOSE: Inter-individual variability in clinical endpoints and occurrence of potentially severe adverse effects represent an enormous challenge in drug development at all phases of (pre-)clinical research. To ensure patient safety it is important to identify adverse events or critical subgroups wit...

Descripción completa

Detalles Bibliográficos
Autores principales: Krauss, Markus, Burghaus, Rolf, Lippert, Jörg, Niemi, Mikko, Neuvonen, Pertti, Schuppert, Andreas, Willmann, Stefan, Kuepfer, Lars, Görlitz, Linus
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer-Verlag 2013
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4230716/
https://www.ncbi.nlm.nih.gov/pubmed/25505651
http://dx.doi.org/10.1186/2193-9616-1-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4230716/
https://www.ncbi.nlm.nih.gov/pubmed/25505651
http://dx.doi.org/10.1186/2193-9616-1-6

Ejemplares similares